NASDAQ:MNOV

MediciNova - MNOV Stock Forecast, Price & News

$2.02

-0.05 (-2.42%)

(As of 03/21/2023 12:00 AM ET)

Add

Compare

Today's Range: $2.00
▼
$2.13
50-Day Range: $1.95
▼
$2.54
52-Week Range: $1.89
▼
$3.18

Volume: 12,321 shs
Average Volume: 28,034 shs
Market Capitalization: $99.08 million

P/E Ratio: N/A
Dividend Yield: N/A
Price Target: N/A

Institutional Ownership

About MediciNova (NASDAQ:MNOV) Stock

MediciNova, Inc. is a biopharmaceutical company, which engages in the acquisition and development of small molecule therapeutics for the treatment of diseases with unmet medical needs. Its development pipeline consists of clinical-stage compounds for the treatment of acute exacerbations of asthma and COPD, progressive multiple sclerosis, methamphetamine addiction, neuropathic pain, asthma, interstitial cystitis, and solid tumor cancers. The company was founded by Yuichi Iwaki on September 26, 2000 and is headquartered in La Jolla, CA.

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Stock News Headlines

March 20, 2023 | americanbankingnews.com

MediciNova (NASDAQ:MNOV) Now Covered by StockNews.com

March 12, 2023 | americanbankingnews.com

StockNews.com Begins Coverage on MediciNova (NASDAQ:MNOV)

March 21, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

In 1990, the Brazilian government froze the bank accounts of thousands of citizens. In 2013, the victims were the people of Cyprus. In 2022, it hit closer to home — in Canada. And now the Federal Reserve System Docket No. OP-1670 reveals the plan to give the Fed the power to track and potentially even control your checking account. Not just the money you have in your account … But also, every single check, withdrawal, deposit and transaction. Practically everything you do with your money!

March 9, 2023 | finance.yahoo.com

MediciNova Announces Additional Extension of BARDA Contract to Develop MN-166 (ibudilast) as a Medical Countermeasure Against Chlorine Gas-induced Lung Injury

February 27, 2023 | finance.yahoo.com

MNOV: Phase 1/2 Clinical Trial of MN-166 in GBM Fully Enrolled…

February 20, 2023 | finance.yahoo.com

MediciNova Announces New Data Regarding MN-166 (ibudilast) in Glioblastoma Tumor Tissue Analysis Presented at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics

February 8, 2023 | finance.yahoo.com

MediciNova Announces Health Canada Grants Authorization to Commence Multi-arm Phase 2/3 Clinical Trial to Evaluate MN-166 (ibudilast) in Long COVID

January 30, 2023 | finance.yahoo.com

MediciNova Announces Completion of Enrollment in the Phase 2b Clinical Trial of MN 166 (ibudilast) in Alcohol Use Disorder

March 21, 2023 | Weiss Ratings (Ad)

Bank Accounts: Frozen!

January 12, 2023 | finance.yahoo.com

MediciNova Announces Completion of Enrollment in the Phase 2 Clinical Trial Evaluating MN-166 (ibudilast) for Treatment of Recurrent and Newly Diagnosed Glioblastoma

January 11, 2023 | finance.yahoo.com

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Scleroderma and Systemic Sclerosis in Canada

January 9, 2023 | finance.yahoo.com

MediciNova Receives a Notice of Allowance for a New Patent Covering MN-001 and MN-002 for the Treatment of Hypertriglyceridemia, Hypercholesterolemia, and Hyperlipoproteinemia in Brazil

January 5, 2023 | finance.yahoo.com

MediciNova to Meet with U.S. FDA to Discuss Clinical Development of a Parenteral Formulation of MN-166 (ibudilast)

December 6, 2022 | finance.yahoo.com

MediciNova Announces Additional Positive Results Regarding the Effects of MN-001 (tipelukast) on Serum Lipid Panel in Type 2 Diabetes and NAFLD Patients Presented at IDF 2022 Congress, the Annual Meeting of the International Diabetes Federation

December 5, 2022 | finance.yahoo.com

MediciNova Announces Positive Results from Secondary Analysis of Phase 2 Trial of MN-166 (ibudilast) Published in The American Journal of Drug and Alcohol Abuse

November 18, 2022 | finance.yahoo.com

MNOV: Well Financed to Get Through Tough Market Conditions…

October 13, 2022 | finance.yahoo.com

We Think MediciNova (NASDAQ:MNOV) Can Afford To Drive Business Growth

October 6, 2022 | reuters.com

MNOV.A - MediciNova, Inc. | Stock Price & Latest News | Reuters

September 29, 2022 | americanbankingnews.com

MediciNova (NASDAQ:MNOV) Earns Hold Rating from Analysts at StockNews.com

September 16, 2022 | seekingalpha.com

MediciNova to get US patent for MN-166 to treat brain cancer - Seeking Alpha

September 15, 2022 | globenewswire.com

MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference - GlobeNewswire

September 15, 2022 | finance.yahoo.com

MediciNova to Participate in the Lytham Partners Fall 2022 Investor Conference

September 15, 2022 | globenewswire.com

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma - GlobeNewswire

September 14, 2022 | nasdaq.com

Health Care Sector Update for 09/14/2022: MNOV, PNT, MRNA, XLV, IBB - Nasdaq

September 14, 2022 | finance.yahoo.com

MediciNova Receives Issue Notification for a New Patent Covering MN-166 (ibudilast) for the Treatment of Glioblastoma

September 14, 2022 | seekingalpha.com

MediciNova to get patent in Canada for MN-001/MN-002 covering certain metabolic disorders

September 14, 2022 | finance.yahoo.com

MediciNova Poised To Receive Canadian Patents For Cholesterol Candidates

See More Headlines

30 days | 90 days | 365 days | Advanced Chart

Receive MNOV Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MediciNova and its competitors with MarketBeat's FREE daily newsletter.

MNOV Company Calendar

Last Earnings: 10/26/2020
Today: 3/21/2023
Next Earnings (Estimated): 3/23/2023
Fiscal Year End: 12/31/2023

Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange: NASDAQ
Industry: Pharmaceutical preparations
Sub-Industry: N/A
Sector: Medical
Current Symbol: NASDAQ:MNOV
CUSIP: N/A
CIK: 1226616
Web: medicinova.com
Phone: (858) 373-1500
Fax: 858-404-0048
Employees: 11
Year Founded: 2000

Profitability

EPS (Most Recent Fiscal Year): N/A
Trailing P/E Ratio: N/A
Forward P/E Ratio: N/A
P/E Growth: N/A
Net Income: $-14,060,000.00
Net Margins: N/A
Pretax Margin: -2,628,577.25%
Return on Equity: -18.73%
Return on Assets: -17.69%

Debt

Debt-to-Equity Ratio: N/A
Current Ratio: 18.51
Quick Ratio: 18.51

Sales & Book Value

Annual Sales: $4.04 million
Price / Sales: 24.53
Cash Flow: N/A
Price / Cash Flow: N/A
Book Value: $1.43 per share
Price / Book: 1.41

Miscellaneous

Outstanding Shares: 49,050,000
Free Float: 40,855,000
Market Cap: $99.08 million
Optionable: Optionable
Beta: 0.98

Social Links

Key Executives

Yuichi Iwaki
President, Chief Executive Officer & Director

Jason Kruger
Chief Financial Officer

Kazuko Matsuda
Director & Chief Medical Officer

Geoffrey G. O'Brien
Vice President & Executive Officer

David H. Crean
Chief Business Officer

Key Competitors

View All Competitors

Insiders & Institutions

View All Insider Transactions
View All Institutional Transactions

MNOV Stock - Frequently Asked Questions

Should I buy or sell MediciNova stock right now?: 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for MediciNova in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" MNOV shares.
View MNOV analyst ratings or view top-rated stocks.
How have MNOV shares performed in 2023?: MediciNova's stock was trading at $2.05 on January 1st, 2023. Since then, MNOV stock has decreased by 1.5% and is now trading at $2.02.
View the best growth stocks for 2023 here.
When is MediciNova's next earnings date?: The company is scheduled to release its next quarterly earnings announcement on Thursday, March 23rd 2023.
View our MNOV earnings forecast.
How were MediciNova's earnings last quarter?: MediciNova, Inc. (NASDAQ:MNOV) released its quarterly earnings results on Monday, October, 26th. The biopharmaceutical company reported ($0.08) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.12) by $0.04.
What other stocks do shareholders of MediciNova own?: Based on aggregate information from My MarketBeat watchlists, some companies that other MediciNova investors own include Dynavax Technologies (DVAX), VBI Vaccines (VBIV), OPKO Health (OPK), Iovance Biotherapeutics (IOVA), Novavax (NVAX), Rigel Pharmaceuticals (RIGL), Trevena (TRVN), Viking Therapeutics (VKTX), Aldeyra Therapeutics (ALDX) and CymaBay Therapeutics (CBAY).

What is MediciNova's stock symbol?: MediciNova trades on the NASDAQ under the ticker symbol "MNOV."
Who are MediciNova's major shareholders?: MediciNova's stock is owned by many different retail and institutional investors. Top institutional investors include Geode Capital Management LLC (0.89%), Jane Street Group LLC (0.55%), Millennium Management LLC (0.51%), JPMorgan Chase & Co. (0.51%), HRT Financial LP (0.37%) and Bank of America Corp DE (0.36%).
View institutional ownership trends.
How do I buy shares of MediciNova?: Shares of MNOV stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.
What is MediciNova's stock price today?: One share of MNOV stock can currently be purchased for approximately $2.02.
How much money does MediciNova make?: MediciNova (NASDAQ:MNOV) has a market capitalization of $99.08 million and generates $4.04 million in revenue each year.
How can I contact MediciNova?: MediciNova's mailing address is 4275 EXECUTIVE SQUARE SUITE 300, LA JOLLA CA, 92037. The official website for the company is medicinova.com. The biopharmaceutical company can be reached via phone at (858) 373-1500, via email at info@medicinova.com, or via fax at 858-404-0048.

This page (NASDAQ:MNOV) was last updated on 3/21/2023 by MarketBeat.com Staff

Get 30 Days of MarketBeat All Access Free

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your 30-Day Free Trial